# Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

Study · id `cardio:ct-nct04160000` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04160000](<https://clinicaltrials.gov/study/NCT04160000>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04160000

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 360 participants.

## Technical summary

Registry record NCT04160000. Randomized; no masking; primary purpose treatment. Start 2020-07-26 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT04160000, source copy `cardio:ctgov-nct04160000-2024-05-23`, retrieved 2026-10-26)
- Started: 2020-07-26 (actual) (ClinicalTrials.gov record NCT04160000, source copy `cardio:ctgov-nct04160000-2024-05-23`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT04160000, source copy `cardio:ctgov-nct04160000-2024-05-23`, retrieved 2026-10-26)
- Completion: 2025-06-30 (anticipated) (ClinicalTrials.gov record NCT04160000, source copy `cardio:ctgov-nct04160000-2024-05-23`, retrieved 2026-10-26)
- Countries: United States; Germany; Switzerland (ClinicalTrials.gov record NCT04160000, source copy `cardio:ctgov-nct04160000-2024-05-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04160000-2024-05-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
- Acronym: TAP-CHF
- Condition: Atrial Fibrillation
- Condition: Heart Failure
- Condition: Diastolic Heart Failure
- Intervention (Device): Catheter ablation
- Intervention (Drug): Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation
- Intervention (Device): Insertion of CardioMems Hemodynamic monitor
- Intervention (Drug): Empiric heart failure drug therapy
- Lead sponsor: Electrophysiology Research Foundation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)

## Provenance

Content hash: 085476d4ce5204ee0233a93e81d590aed9ad5056182346c31d63272f883c66ee
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
